IOBiotech

Today, we welcome Devin Smith as new General Counsel. Mr. Smith brings more than 25 years of legal and compliance experience in the life sciences industry. For more details on his appointment, click here: bit.ly/3J961rp

We’re developing a pipeline of product candidates that leverage our T-win technology to disrupt immune suppressive elements of the #tumor microenvironment to create medicines that could bring therapeutic benefit to patients in need. Explore our pipeline: bit.ly/3Vj1XIk

Today we announced a business update including encouraging initial data from our Phase 2 basket study evaluating our lead asset in combination with pembrolizumab in Non-small Cell Lung Cancer #NSCLC. For more details, click here: bit.ly/3QoLqAQ

#ICYMI, check out this @ACIR_org summary of Professor Mads Andersen’s @sitcancer presentation featuring the history behind our immune modulating #vaccines against #cancer and results from the MM1636 Phase 1/2 trial in #melanoma. Click for more: bit.ly/3GUeDkK #SITC22

#HappyHolidays from our team here at IO Biotech! We wish everyone a happy holiday season, and we look forward to continuing our work to advance our novel, immune-modulating #cancer vaccines in the new year!

We will be attending! From January 9-11, LifeSci Partners will be hosting their 12th Annual Corporate Access Event in San Francisco, with over 125 life sciences companies in attendance. Learn more about the event here: bit.ly/3FuXdu4

CEO, @ZoccaMai, spoke with @BenMComer from Life Science Leader to discuss which countries or markets outside of the U.S. will be most important for biopharma companies to focus on in 2023. Read more on what she had to say here: bit.ly/3VK9PTr

Join us at Melanoma Bridge 2022, December 1-3 in Naples, Italy where we will present a poster on our Trials in Progress. Learn more: bit.ly/3XnQ9WB

We are looking forward to Melanoma Bridge 2022 where Alexander Eggermont, M.D., Ph.D. will give a talk on our ongoing Phase 3 trial in #melanoma. Learn more: bit.ly/3XnQ9WB

We’re proud to announce that our CEO @ZoccaMai won the European @lifestarsawards Women-led Business Leader of the Year Award. Mai-Britt is a natural-born leader who has made significant contributions to the #biotech industry for 20+ years. Congrats to all the winners & nominees!

Our CEO @ZoccaMai Ph.D., & CFO Amy Sullivan, are attending the @Jefferies London Healthcare Conference. They will be participating in a fireside chat about our clinical programs & our proprietary technology platform to treat #cancer. Click here: bit.ly/3UXAc7p $IOBT

Good luck to our CEO @ZoccaMai Ph.D., a finalist for this year's Women-Led Business Leader of the Year for #Nordic region at tonight's @lifestarsawards ceremony bit.ly/3tptBXX

We’re pleased to announce details of the invited oral presentation & two posters at @sitcancer where we will be showcasing new preclinical data for 2 new pipeline candidates targeting ARG1 & TGFβ1. For more details on the presentation, click here: bit.ly/3NW9U3s #SITC22

Today, we announced our third quarter financial results for 2022. Explore our ongoing programs and find a recap of our most recent corporate developments here: bit.ly/3hvRzy0 $IOBT

Come see our talented scientists, Marion Chapellier, Ph.D. & Brian Weinert, Ph.D. who will be presenting posters highlighting the next two #immunosuppressive targets in our pipeline at @sitcancer. Click here to learn more about their presentations: bit.ly/3W271Sc #SITC22

We’re pleased to announce our fourth clinical collaboration to evaluate our lead immune-modulating candidate in combination with pembrolizumab in a Phase 2 trial in patients with resectable tumors. For more details, click here: bit.ly/3Uliv1p $IOBT

Join our CEO @ZoccaMai Ph.D., & CFO Amy Sullivan, at the @Jefferies London Healthcare Conference, November 15 – 17, 2022 where they will be participating in a fireside chat and one-on-one investor meetings. For more details, click here: bit.ly/3Nptcho $IOBT

Are you attending this year’s @SocietyMelanoma #2022Congress in Edinburgh, U.K.? Check out our CMO Eva Ehrnrooth, M.D., Ph.D., who will be presenting a Trials in Progress poster on our Phase 3 global trial in #melanoma. Click for more details: bit.ly/3F5HJwD

Today, we welcomed to the executive team, Amy Sullivan, as our new Chief Financial Officer. Ms. Sullivan is a seasoned life sciences professional with more than 25 years of experience within the industry. For more details on her appointment, click here: bit.ly/3MJjmXn

Our CEO @ZoccaMai, Ph.D., is participating in the Virtual @ShareVault Webinar, “Biotech Decision-Making During Uncertain Times,” tomorrow at 8am PST / 11am EST where she’ll discuss the current state of the #biotech market. Register here: bit.ly/3TePUKM